

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S. Patent and Trademark Office, Box Sequence
P.O. Box 2327, Arlington, VA 22202 on:

April 27, 2005

David Saliwanchik
David R. Saliwanchik, Patent Attorney

AMENDMENT UNDER
37 CFR 1.825(a) THROUGH (c)
Confirmation No. 4903
Patent Application
Docket No. GJE-7452
Serial No. 10/507,268

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Seppo Yla-Herttuala, Kari Juhani Airene
Serial No. : 10/507,268
Filed : September 9, 2005
Conf. No. : 4903
For : Engineered Baculoviruses and Their Use

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows: